CA9/CAIX (carbonic anhydrase 9) is a zinc metalloenzyme catalyzing the reversible hydration of carbon dioxide. Physiologically, CA9 participates in a variety of biological processes including respiration, calcification, acid-based balance, bone resorption, and the formation of aqueous humor, cerebrospinal fluid, saliva, gastric acid, etc. as a transmembrane protein, and involves in cell proliferation and transformation. With persistent efforts, researchers have revealed that CA9 expression levels associate with various clinicopathological outcomes. For instance, CA9 is now regarded as a cellular biomarker of hypoxia. Furthermore, it is expressed in all clear-cell renal cell carcinoma (ccRCC) and hypoxic solid tumors as one of the only two known tumor-associated carbonic anhydrase isoenzymes, while undetectable in normal kidney and most other normal tissues. In addition, Girentuximab, an anti-CA9 monoclonal Ab, has been investigated in clinical trials for RCC. Creative Biolabs is able to help researchers to initiate the very first anti-CA9 CAR-T cell therapy.
A mouse with a subcutaneous CA9-positive ccRCC and proposed structural model of CA9 dimer on the cellular membrane
Proceedings of the National Academy of Sciences 106.38 (2009): 16233-16238
European urology 58.1 (2010): 75-83
Anti-CA9 CAR-T Cell Therapy
CA9 has been targeted with multiple monoclonal Abs in clinical trials for the treatment of RCC which have resulted in limited efficiency, and the pilot pre-clinical and clinical CAR-T cell therapy has not yet been reported. Creative Biolabs helps researchers fill in the blank for the cutting-edge immunotherapy.
Animal Models for in vivo Study of anti-CA9 CAR-T Cell Therapy
Creative Biolabs offers researchers almost every particular animal model in the world via the major techniques including the conventional carcinogen-induced models, the mosaic transposon- or virus-induced models, the transgenic models and the subcutaneous or patient-derived xenograft models, and the talented creation of specific requirement to make a stand against RCC.
Development143.4 (2016): 595-608
In vivo Assay Parameters and Techniques
At Creative Biolabs, we offer the most exquisite and comprehensive service platform for preclinical anti-CA9 CAT-T cell therapy research.
Tumor remission monitored by tumor volume recording or bioluminescence imaging and survival curve tracking
Viability and Bio-distribution Studies
Durability, GLP-compliant bio-distribution studies
Pilot tolerability (MTD, The route of administration, Dose regimen/response/onset)
Clinical observation (body weight, feed consumption, ophthalmologic and clinical pathology)
Cytokine storm surveillance (fever, hypertension, prolonged cytopenia)
Complete necropsy, organ weight
You request, Creative Biolabs offers the best.
For any technical issues or products/services related questions, please leave your information below. Our team will contact you soon.
Nanoparticle Tiny Tech for Programming T Cells: A novel technology to increase the efficiency and value of your CAR-T therapy project.LEARN MORE
Angiotensin-converting Enzyme 2 (ACE2)-CHO Cell Line Model for COVID-19: Helps researchers to further study the interaction between the receptor ACE2 and the COVID-19 virus.LEARN MORE
TRAC-CAR-T Cell Development with CRISPR/Cas9 Technology: A novel technology to build more powerful CAR-T cells.LEARN MORE